Editor’s Note: In a new white paper, summarized below, Manatt Health discusses emerging reimbursement models for cell and gene therapies. The paper provides an overview of current Medicaid, Medicare and commercial coverage,...more
7/26/2023
/ Centers for Medicare & Medicaid Services (CMS) ,
DNA ,
Food and Drug Administration (FDA) ,
Genetic Materials ,
Health Insurance ,
Healthcare ,
Life Sciences ,
Medicaid ,
Medicare ,
Pharmaceutical Industry ,
Value-Based Payments
Over the past five years, cell and gene therapies have increasingly moved from the R&D pipeline to the health care setting, putting lifesaving treatments for certain cancers and genetic diseases within patients’ reach. Over...more
7/20/2023
/ Clinical Trials ,
Food and Drug Administration (FDA) ,
Health Insurance ,
Healthcare ,
Human Genes ,
Life Sciences ,
Medicaid ,
Medical Devices ,
Medical Reimbursement ,
Medical Research ,
Medicare ,
Pharmaceutical Industry
Editor’s Note: In a recent webinar, Manatt Health’s Anthony Fiori, Senior Managing Director, and Alex Dworkowitz, Partner, hosted a panel of innovative thought leaders—including Dr. Sanjiv Shah, Chief Medical Officer of...more
10/28/2021
/ Biologics ,
Biotechnology ,
Drug Pricing ,
Financing ,
Genetic Materials ,
Genetic Testing ,
Health Care Providers ,
Healthcare Reform ,
Human Genes ,
Life Sciences ,
Manufacturers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Rebates ,
Reinsurance ,
Value-Based Purchasing
The Search for Savings and Value: The Federal Perspective -
President Trump’s “American Patients First” blueprint outlines several initiatives to lower drug prices and reduce patients’ out-of-pocket costs. Shortly after...more
Editor’s Note: State Medicaid programs continue to balance serving eligible beneficiaries and controlling costs. In an environment sharply focused on the cost of drugs, it is increasingly critical to understand the Medicaid...more